<?xml version="1.0" encoding="UTF-8"?>
<p id="Par21">All the vaccine candidates have performed well in mice and nonhuman primates (NHPs), and a neutralization titer of approximately 1 in 100 could prevent viremia in ZIKV-challenged animals immunized with candidate vaccines [
 <xref ref-type="bibr" rid="CR6">6</xref>–
 <xref ref-type="bibr" rid="CR10">10</xref>]. This compares with neutralization titers of 1 in 10 for other licensed flavivirus vaccines, indicating that greater quantities of anti-ZIKV antibodies are required for protection, at least in animal models. Only the live attenuated [
 <xref ref-type="bibr" rid="CR5">5</xref>] and RNA [
 <xref ref-type="bibr" rid="CR9">9</xref>] ZIKV vaccine candidates induced sterilizing immunity in mice (but not in NHPs), requiring a neutralization titer of around 1 in 5000. Recent studies have shown that PIV and an adenovirus-vectored vaccine gave protective immunity in NHPs at 1 year postimmunization, whereas a DNA vaccine did not [
 <xref ref-type="bibr" rid="CR11">11</xref>]. Importantly, of the vaccines described here, only the PIV was the same as that in the clinical evaluation.
</p>
